Search
In recent years, the interest in molecular diagnostic methods for the detection of many pathogens has grown substantially.
Co-designed and in collaboration with community members, the impacts of this project will directly benefit families by building awareness, empowering decision-making, and improving confidence around the recognition and management of skin conditions for Aboriginal children.
Asha Jonathan Marianne Bowen Carapetis AM Mullane BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) Head, Healthy Skin
Healthy skin is important for maintaining overall health and wellbeing. Some skin infections, if untreated, can lead to serious downstream health complications such as heart disease, kidney disease, or sepsis.
The aim of this project is to conduct a situational analysis of the skin health services and activities currently available for managing skin infections within the Kimberley.
The skin is home to an array of bacteria, fungi and viruses, which together make up the skin microbiome. We explore how the skin microbiome can contribute to healthy skin.
Dr Anita Asha Campbell Bowen MBBS, DCH, PG DipPID, FRACP, PhD BA MBBS DCH FRACP PhD GAICD FAHMS OAM Infectious Diseases Physician; Raine Clinician
Head lice is an ectoparasitic skin infection commonly seen in primary school-aged children. In remote Australia, where rates of other skin infections and downstream sequelae are endemic, the rate of head lice infestation is unknown.
Asymptomatic carriage of Streptococcus pyogenes (Strep A) may contribute to transmission, yet its role remains poorly understood and evidence on optimal detection methods is limited. While self-collected throat swabs are used in infectious disease surveillance, their value for identifying asymptomatic Strep A carriage in adults is uncertain. This pilot prospective cohort study, conducted at a Perth medical research institute between August and October 2024, assessed feasibility and acceptability of self-collection, with sensitivity as a secondary objective.
Citation: MacDonald B, Burmaz M, Baker S, et al. TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in